Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin - Takeda

Drug Profile

Immune globulin - Takeda

Alternative Names: 10% HyQ; 20% SubQ; Cuvitru; Gammagard Liquid; Gammagard S/D; Human Immune Globulin for Subcutaneous Administration; HyQ; HyQvia; Ig20Gly; IGI 10% with rHuPH20; IGIV - Baxalta; IGSC - Baxalta; immune globulin intravenous; IVIG 10%; Kiovig; SCIG 20%; SHP-671; TAK 771

Latest Information Update: 18 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baxter International
  • Developer Baxter International; Halozyme Therapeutics; Shire; Takeda
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic inflammatory demyelinating polyradiculoneuropathy; Peripheral nervous system diseases
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allotransplant rejection; Chronic lymphocytic leukaemia; Guillain-Barre syndrome; HIV infections; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Peripheral nervous system diseases
  • Phase III Chronic inflammatory demyelinating polyradiculoneuropathy
  • Phase II Ataxia
  • Suspended Alzheimer's disease

Most Recent Events

  • 07 Nov 2019 Pooled results from phase II/III European and North American trial in Immunodeficiencey disorders presented at the 2019 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (AAAAI-2019)
  • 22 Feb 2019 Updated adverse events data from the phase II/III North American trial in Immunodeficiency disorders presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2018)
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top